Rafferty Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.98M | Buy |
163,616
+49,022
| +43% | +$2.66M | 0.02% | 320 |
|
|
2026
Q1 | $7.19M | Sell |
114,594
-45,012
| -28% | -$3.6M | 0.03% | 294 |
|
|
2025
Q4 | $15.2M | Sell |
159,606
-4,873
| -3% | -$478K | 0.05% | 207 |
|
|
2025
Q3 | $16.1M | Buy |
164,479
+8,101
| +5% | +$839K | 0.05% | 203 |
|
|
2025
Q2 | $16.8M | Buy |
156,378
+19,915
| +15% | +$2.02M | 0.06% | 173 |
|
|
2025
Q1 | $13.8M | Sell |
136,463
-30,681
| -18% | -$3.09M | 0.06% | 199 |
|
|
2024
Q4 | $14.9M | Buy |
167,144
+17,781
| +12% | +$1.57M | 0.05% | 210 |
|
|
2024
Q3 | $12.5M | Sell |
149,363
-10,532
| -7% | -$830K | 0.04% | 242 |
|
|
2024
Q2 | $12.3M | Buy |
159,895
+8,706
| +6% | +$637K | 0.05% | 250 |
|
|
2024
Q1 | $10.4M | Buy |
151,189
+2,133
| +1% | +$137K | 0.04% | 260 |
|
|
2023
Q4 | $8.62M | Sell |
149,056
-3,724
| -2% | -$199K | 0.04% | 318 |
|
|
2023
Q3 | $8.07M | Buy |
152,780
+13,624
| +10% | +$715K | 0.05% | 282 |
|
|
2023
Q2 | $7.53M | Buy |
139,156
+10,990
| +9% | +$574K | 0.04% | 308 |
|
|
2023
Q1 | $6.41M | Buy |
128,166
+4,932
| +4% | +$232K | 0.04% | 324 |
|
|
2022
Q4 | $5.7M | Buy |
123,234
+46,641
| +61% | +$2.02M | 0.05% | 350 |
|
|
2022
Q3 | $2.97M | Buy |
76,593
+41,908
| +121% | +$1.68M | 0.03% | 417 |
|
|
2022
Q2 | $1.29M | Sell |
34,685
-8,873
| -20% | -$361K | 0.01% | 572 |
|
|
2022
Q1 | $1.93M | Sell |
43,558
-4,337
| -9% | -$188K | 0.01% | 610 |
|
|
2021
Q4 | $2.04M | Buy |
47,895
+2,498
| +6% | +$105K | 0.01% | 655 |
|
|
2021
Q3 | $1.97M | Buy |
45,397
+15,985
| +54% | +$707K | 0.01% | 638 |
|
|
2021
Q2 | $1.26M | Buy |
29,412
+2,671
| +10% | +$112K | 0.01% | 804 |
|
|
2021
Q1 | $1.03M | Buy |
26,741
+3,138
| +13% | +$119K | 0.01% | 762 |
|
|
2020
Q4 | $849K | Sell |
23,603
-2,217
| -9% | -$79.9K | 0.01% | 550 |
|
|
2020
Q3 | $987K | Sell |
25,820
-6,282
| -20% | -$242K | 0.01% | 582 |
|
|
2020
Q2 | $1.13M | Buy |
32,102
+21,377
| +199% | +$770K | 0.02% | 508 |
|
|
2020
Q1 | $350K | Sell |
10,725
-26,913
| -72% | -$1.05M | 0.01% | 404 |
|
|
2019
Q4 | $1.7M | Buy |
+37,638
| New | +$1.57M | 0.03% | 436 |
|
|
2016
Q4 | – | Sell |
-26,043
| Closed | -$620K | – | 458 |
|
|
2016
Q3 | $620K | Buy |
+26,043
| New | +$621K | 0.02% | 309 |
|
|
2016
Q2 | – | Sell |
-85,196
| Closed | -$1.6M | – | 512 |
|
|
2016
Q1 | $1.6M | Buy |
+85,196
| New | +$1.5M | 0.09% | 170 |
|
|
2015
Q4 | – | Sell |
-77,617
| Closed | -$1.27M | – | 533 |
|
|
2015
Q3 | $1.27M | Buy |
+77,617
| New | +$1.33M | 0.1% | 186 |
|
|
2015
Q1 | – | Sell |
-60,214
| Closed | -$798K | – | 564 |
|
|
2014
Q4 | $798K | Buy |
+60,214
| New | +$770K | 0.18% | 127 |
|
|
2013
Q3 | – | Sell |
-15,629
| Closed | -$145K | – | 174 |
|
|
2013
Q2 | $145K | Buy |
+15,629
| New | +$133K | 0.02% | 262 |
|
Other funds holding BSX
Rafferty Asset Management's BSX Position: Q2 2026 in Review
Rafferty Asset Management increased its Boston Scientific (BSX) stake by 43% in Q2 2026, buying an estimated $2.66M and bringing the position to 163,616 shares worth $6.98M. The position accounts for 0.02% of the portfolio, ranked #320.
Rafferty Asset Management first reported a position in BSX in Q2 2013 and has held it in 32 quarters since. The position peaked at $16.8M in Q2 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Rafferty Asset Management held 163,616 shares of Boston Scientific worth $6.98M as of Q2 2026.
- Rafferty Asset Management bought 49,022 Boston Scientific shares in Q2 2026, an estimated $2.66M.
- Boston Scientific made up 0.02% of Rafferty Asset Management's portfolio in Q2 2026, its #320 holding.
- Rafferty Asset Management first reported a position in Boston Scientific in Q2 2013 and has held it in 32 quarters since.
- Rafferty Asset Management's Boston Scientific position peaked at $16.8M in Q2 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.